This article reviews the profile of perampanel, a novel noncompetitive a-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) receptor antagonist, and its role as a potential broad-spectrum antiepileptic drug in the treatment of epilepsy. For this narrative review, data were collected using specified search criteria. Articles reporting the evidence for perampanel's efficacy from preclinical models, phase 3 clinical studies, observational studies, and descriptive evidence were included. AMPA receptors play a key role in mediating the action of glutamate at the excitatory synapse. Preclinical research showed the AMPA receptor blockade to constitute a promising target for antiepileptic drug therapy. In animal models, perampanel proved to be protective against seizures and reduce seizure severity and duration. Four phase-3 randomized controlled trials (3 in patients with focal seizures and one in primary generalized tonic-clonic seizures in idiopathic generalized epilepsy) have been completed. In focal (partial) onset seizures, perampanel (4, 8, and 12 mg) significantly reduced seizure frequency per 28 days (23.3%-28.8% vs 12.8%; P < .01) and responder rates (≥50% reduction in seizures) (28.5%-35.3% vs 19.3%; P < .05) compared with placebo. In primary generalized tonic-clonic seizures, perampanel 8 mg resulted in greater reduction in seizure frequency per 28 days (À76.5% vs À38.4%; P < .0001) and responder rate (64.2% vs 39.5%; P = .0019) than placebo.
specific category (focal seizures, also termed partial onset seizures, vs primary generalized seizures), whereas "broad-spectrum" AEDs are considered to be effective against several seizure types (both focal and primary generalized seizures). 3, 4 However, there is no universally accepted definition of the term "broad spectrum." For the purpose of this article, "broad spectrum" is used when efficacy against focal seizures with or without secondary generalization and primary generalized seizures (of any type) has been shown in large randomized trials (International League Against Epilepsy [ILAE] class I, II, or III, such as the Standard And New Antiepileptic Drugs [SANAD] study 7, 8 ).
The characteristic mechanisms of action that distinguish broad-spectrum from narrow-spectrum AEDs have not been elucidated. Until the development of the newer generations of AEDs in the 1990s, only valproate was considered to have broad-spectrum efficacy against all seizure types. 3, 4, 6 Since then, newer AEDs with a broader spectrum of activity in specific epileptic syndromes and seizure types have emerged, 3, 4 including zonisamide, 9 topiramate, 10 lamotrigine, levetiracetam, 11, 12 and brivaracetam. 13 Some broad-spectrum
AEDs have multiple mechanisms of action. 4 For example, zonisamide acts by inhibiting voltage-gated ion channels, inhibiting low-threshold T-type calcium currents, enhancing c-aminobutyric acid release, and inhibiting glutamatergic neurotransmission. 9 On the other hand, some narrow-spectrum AEDs may not only be ineffective for some seizures, but also harmful, by inducing or aggravating specific seizure types or seizures associated with specific epilepsy syndromes. 6, 14 For example, several sodium channel modulators can aggravate and induce seizures in absence epilepsy, juvenile myoclonic epilepsy, and other idiopathic generalized epilepsies. 15 The treatment choice depends on the seizure type and the epileptic syndrome. However, characterization of the seizure type at the time of diagnosis is often very difficult or even impossible, and misdiagnosis after a first seizure occurs in approximately 5%-30% of patients. 16, 17 Therefore, broad-spectrum AEDs are a logical choice for initial firstline treatment, particularly during the diagnostic period, after which the treatment can be tailored to the epilepsy syndrome and individual patient factors. 6 Resistance to pharmacotherapy occurs in approximately 30%-40% of patients with epilepsy despite recent progress in the development of new AEDs. 18, 19 The prevalence of drug-resistant epilepsy ranges from 15.6% to 37%. [20] [21] [22] [23] Drug-resistant epilepsy can lead to increased morbidity and mortality, as well as social disability. [24] [25] [26] Sudden unexpected death in epilepsy (SUDEP) is the most frequent epilepsy-related cause of death, 18 accounting for approximately 17% of epilepsy-related mortality. 27 The primary risk factor for SUDEP is recurrent generalized tonicclonic (GTC) seizures, with odds ratios of 2.94 for 1-2 seizures/year, 8.28 for 3-12 seizures/year, 9.06 for 13-50 seizures/year, and 14.51 for >50 seizures/year. 28 Other risk factors include long duration of epilepsy, young age at onset, nocturnal seizures, lack of seizure control, and polytherapy. [29] [30] [31] In a UK study, 48 of 93 epilepsy-related deaths met the criteria for SUDEP over a 9-year period, and 91.3% of the SUDEP population had increasing seizure frequency and severity in the preceding 6 months. 31 Thus, development of new improved treatments with novel mechanisms of action and a potential broad spectrum of efficacy for drug-resistant epilepsy continues. Perampanel is one such AED that was developed as an orally active selective noncompetitive a-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) receptor antagonist. 32, 33 Perampanel has been approved as adjunctive therapy for focal seizures with or without secondarily generalized seizures in patients aged 12 years or older in >55 countries, including Australia, North America, Europe, Asia, and Russia. Perampanel has also been approved as adjunctive therapy for primary generalized tonic-clonic (PGTC) seizures in North America, Europe, Asia, and Russia in patients aged 12 years or older. This article reviews the preclinical evidence from animal models and describes the clinical experience with perampanel, and its place in real-world clinical practice as a potential broad-spectrum AED.
| METHODS
For this narrative review, data were collected from Medline/PubMed , and Embase using specified search criteria (papers published in English). The search terms were combinations of the following: 'epilepsy', 'antiepileptic drugs',
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• Perampanel is a useful adjunctive therapy for refractory focal seizures with or without secondary generalization and primarily generalized tonic-clonic seizures POTSCHKA AND TRINKA 'AMPA receptor', 'perampanel', 'preclinical', 'animal model', 'broad/narrow spectrum', 'clinical', 'treatment', and terms relating to study type. If a title or abstract described a high-quality article that was likely to be eligible for inclusion, the full article was obtained and assessed for relevance. Articles describing the preclinical research and clinical experience with perampanel were included.
| TARGETING THE AMPA RECEPTOR
Glutamate is the primary excitatory neurotransmitter in the central nervous system. 33, 34 AMPA and NMDA receptors generate the depolarization underlying seizure-like discharges. A study in guinea pig hippocampal slices that generate seizure-like discharges in the presence of picrotoxin demonstrated that blocking NMDA receptors with (2R)-amino-5-phosphonovaleric acid eliminates late bursting, but does not stop the initial seizure-like discharge. 37 However, blocking AMPA receptors with 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) eliminates the seizure-like discharge. 37 Further evidence for upregulation of AMPA receptors in epilepsy comes from autoradiographs showing increased AMPA receptor density in tissue resected from patients with epilepsy. 38 Pathways of seizure generalization appear to be similar for all GTC seizures, irrespective of whether they are focal-onset or PGTC seizures. 39 Postsynaptic AMPA receptors are involved in distribution of excitatory signals in GTC seizures. In PGTC seizures, widespread thalamocortical interconnections cause rapid activation of both hemispheres, whereas in focal seizures, spread to subcortical thalamic centers results in secondary generalization. 39 Thus, it could be expected that an AED that is effective in treating secondarily generalized seizures would also have efficacy in PGTC seizures, but this is not the case, although the reason for this paradox is unclear. Perampanel blocks excitatory neurotransmission by targeting glutamate activity postsynaptically. [33] [34] [35] 40 Because perampanel is not displaced under high agonist concentrations, it can block raised glutamate levels, demonstrating potent antiseizure activity. 33, 34 Thus, lower doses of perampanel are required for protection from seizures than might be needed from a competitive agonist, implying that adverse events (AEs) can be minimized. 34 AMPA antagonism with perampanel has been shown to inhibit excitatory postsynaptic field potentials in the hippocampus following Schaffer collateral stimulation, with a half maximal inhibitory concentration of 0.23 lmol/L and full inhibition at 3 lmol/L. 41 These concentrations are similar to plasma levels of perampanel following effective antiseizure doses and support its main mechanism of action being AMPA receptor antagonism.
| PRECLINICAL EVALUATION OF EFFICACY, SAFETY, AND TOLERABILITY
AMPA receptor antagonists have demonstrated antiseizure activity in several preclinical epilepsy models, 42 suggesting therapeutic potential as an AED. Noncompetitive AMPA receptor antagonists such as perampanel are considered more efficacious than competitive AMPA receptor antagonists. 42 In vitro assays suggest that perampanel is selective for AMPA receptors, while not affecting NMDA receptors, although the precise mechanism of action remains to be fully elucidated. 40, 41 The preclinical assessment of perampanel is summarized in Table 1 . 40, [43] [44] [45] [46] Perampanel protected mice from GTC seizures in audiogenic models and maximal electroshock-induced tests at lower median effective dose values than carbamazepine or valproate. 40 In an amygdala-kindled rat model designed to reflect refractory epilepsy, high-dose perampanel resulted in significant reductions in seizure severity that did not occur with levetiracetam, lamotrigine, carbamazepine, valproic acid, or low-dose perampanel (P < .0001). When low-dose perampanel was combined with each of these AEDs, seizure severity was significantly reduced compared with each drug given alone (P < .05). 40, 43 With suprathreshold stimulation, perampanel failed to abolish electroencephalographic (EEG) seizures at source, but significantly reduced seizure severity and duration compared with levetiracetam, lamotrigine, carbamazepine, valproate, or control, suggesting that perampanel may inhibit seizure propagation as well as increase seizure threshold.
40
A study evaluating the antiseizure effects of combination therapy with perampanel and zonisamide in a rat amygdala kindling model found a pronounced synergistic effect. 44 When given alone, perampanel and zonisamide each dose-dependently increased the afterdischarge threshold. Perampanel significantly reduced seizure severity, seizure duration, and afterdischarge duration (P < .05), whereas these parameters were unaffected by zonisamide. When zonisamide was combined with perampanel, pronounced afterdischarge threshold increases were observed in a synergistic interaction. In an analysis of the therapeutic index, high-dose perampanel 1.5 mg/kg plus zonisamide 40 mg/kg demonstrated pronounced antiseizure effects, but also caused motor impairment, whereas lower perampanel doses resulted in a highly efficacious and well-tolerated combination. This synergistic effect with a favorable tolerability profile at low perampanel doses suggests that this combination might be efficacious for clinical management of focal seizures.
The intrahippocampal kainate mouse model was used to evaluate the antiseizure effects of competitive (NBQX) and noncompetitive (perampanel) AMPA receptor antagonists in resistant focal seizures. 47, 48 Whereas phenytoin did not block the spontaneous seizures that developed following kainate administration, both NBQX and perampanel suppressed the seizures, suggesting efficacy in treating resistant focal seizures. In a separate experiment, administration of NBQX for 3 days following kainate administration did not produce an antiseizure effect. 48 Perampanel was not evaluated with a comparable treatment protocol.
Animal studies suggest that AMPA receptor-mediated glutamatergic transmission increases during status epilepticus (SE) and that AMPA receptor plasticity may be involved in maintaining SE. [49] [50] [51] In a rat model of absence seizures and behavior, perampanel temporarily modified development of absence seizures and comorbid depression. 45 Perampanel, 3 mg/kg, significantly reduced the number and duration of spontaneous spike-wave discharges at 6 months (P < .028), but not at 10 months. Perampanel, 1 and 3 mg/kg. significantly reduced immobility time and increased sucrose preference (indicators of a depression-like condition) at 6 months (P < .05), but not at 10 months. These results support the involvement of AMPA receptors in epileptogenesis and suggest an antiepileptogenic effect of perampanel in absence epilepsy. Of interest is the potential neuroprotective effect of perampanel, as shown in a model of traumatic brain injury (TBI) in rats. 52 Administration of perampanel following TBI significantly decreased brain edema and brain contusion volume and preserved motor function; reduced cognitive dysfunction, neuronal apoptosis, and oxidative stress; and maintained the endogenous antioxidant system. Perampanel also attenuated the expression of tumor necrosis factor-a and interleukin (IL)-1b at 24 hours (but not 4 hours) postinjury, and increased levels of IL-10 and transforming growth factor-b1 at 4 and 24 hours. These results suggest that perampanel might protect against the neurologic consequences of TBI through anti-oxidative and anti-inflammatory activity. Perampanel was not found to be neuroprotective in trials of multiple sclerosis or Parkinson disease, although the doses tested were low (0.5-4.0 mg/ d). provide ILAE class I evidence that adjunctive perampanel at 4, 8, and 12 mg is effective in patients with refractory focal seizures. The most frequent treatment-emergent AEs (TEAEs; occurring in ≥10% of patients in any group) were dizziness, somnolence, headache, fatigue, fall, irritability, and ataxia. [56] [57] [58] [59] Most TEAEs were mild to moderate in severity.
Psychiatric TEAEs (occurring in >1% of patients in any group) were sleep disorder, anxiety, aggression, confusional state, and anger. [56] [57] [58] [59] Psychiatric and behavioral TEAEs analyzed by broad and narrow MedDRA Standardized Medical Queries found that hostility/aggression events occurred more frequently with perampanel than with placebo and were dose-related. 60 The most common event was irritability, followed by aggression. However, serious psychiatric AEs were uncommon. Some AEs occurred more frequently during the titration period than during the maintenance period, and at higher doses, suggesting a possible relationship with the fast titration schedule. 56 Long-term data from an open-label extension study to the phase 3 trials show that overall median percent seizure reduction was 70.6% and median percent reduction for secondarily generalized seizures was 100% after 4 years of treatment with perampanel. 61 The responder rate was 67.9%. No new safety signals were noted during this longterm exposure to perampanel.
| PGTC seizures
More recently, perampanel was approved for PGTC seizures based on ILAE class I evidence of reduced seizure frequency compared with placebo in patients with refractory PGTC seizures in idiopathic generalized epilepsy (study 332). 62 In this study, the diagnosis was independently confirmed by reviewers from the Epilepsy Study Consortium, and 30% of patients were excluded for misdiagnosis or unconfirmed diagnosis before the start of the study, providing high external validity. Compared with placebo, perampanel 8 mg resulted in greater median percent change in PGTC seizure frequency per 28 days (À76.5% vs À38.4%; P < .0001) and greater responder rate (64.2% vs 39.5%; P = .0019). Seizure freedom was achieved by 30.9% of patients with perampanel 8 mg and 12.3% with placebo. Perampanel was well tolerated, with the most common TEAEs being dizziness, headache, and fatigue. 62 It is notable that there was no evidence to suggest that perampanel aggravated absence seizures or myoclonic seizures compared with placebo. 63 In a subanalysis to study 332, absence seizure worsening occurred in 29.6% of patients taking perampanel and 45.5% of patients taking placebo; myoclonic seizure worsening occurred in 29.2% and 30.4%, respectively. 64 The response rates for absence seizure freedom were 22.2% for perampanel vs 12.1% for placebo, and 16.7% vs 13.0%, respectively, for myoclonic seizure freedom.
In an open-label extension to study 332 of up to 2.5 years (136 weeks), the median percent reduction in PGTC seizure frequency was 91.3% among 68 patients taking perampanel, and responder rate was 75%. 65 The clinical benefits and tolerability over the longer term were similar to those in study 332. Retention rates in real-world clinical practice are relatively high at 44%-89%, with the greatest retention in patients receiving slow titration (<2 mg every 2 weeks). 69 Long-term real-world data are available from a hospital chart review of perampanel with a median treatment duration of 20.1 months (range 3.4-26.8 months). 70 Of 122 patients with focal seizures with or without secondary generalization receiving perampanel, 71 (58%) were taking perampanel at the last follow-up. Thirty-three patients (27%) had been seizure-free for ≥3 months, 8 (7%) of whom achieved seizure freedom for ≥3 times the longest interictal interval before starting perampanel and 18 (15%) had ≥50% reduction in seizure frequency. Six patients (5%) had increased seizure frequency. A French study retrospectively reviewed data from 101 adult epilepsy patients with learning disability and/or psychiatric comorbidity. 71 The epilepsy types were structural/ metabolic (57.4%), unknown (26.7%), Lennox-Gastaut syndrome (2%), and other types (13.9%); 28.7% of patients had temporal epilepsy and 71.3% had extratemporal epilepsy. The mean retention was 8.1 months. Reduction in seizure frequency ≥50% was achieved by 41.6% of patients; 6.9% became seizure-free and 9.9% had a partial response (<50% seizure reduction). Treatment retention, efficacy, and safety were similar in patients with and without learning disability or psychiatric comorbidity. The only significant difference was that 11.1% of patients without learning disability achieved seizure freedom compared with 0% of patients with learning disability (P = .043). The most common AEs were irritability, asthenia, aggression, and sedation. Among the 50 patients (49.5%) with psychiatric comorbidity, the prevalence of AEs was similar to that in patients without psychiatric comorbidity (66.0% vs 58.3%, compared with 62.4% overall). Thus, psychiatric comorbidity did not appear to be a contraindication for perampanel in this group of patients, although counseling about the potential for psychiatric AEs is recommended prior to starting treatment with perampanel. A single-center study retrospectively evaluated the efficacy of perampanel in 101 patients with focal seizures (25%), secondarily generalized tonic-clonic (SGTC) seizures (35%), PGTC seizures (32%), and other seizure types (absence, myoclonic, and infantile spasms; 9%). 72 The average treatment duration was 8.2 months and the average dose of perampanel was 6.5 mg. Perampanel was as effective in children (age <12 years) as in adults (50% [P = .002] and 33% [P < .0001] seizure frequency reduction, respectively). Seizure frequency reduction was 44% (P = .0008) for PGTC seizures, 38% (P = .0002) for SGTC seizures, and 33% (P < .0001) for focal seizures; responder rates were 53% for PGTC seizures, 43% for SGTC seizures, 60% for focal seizures, and 56% for other seizure types. AEs occurred in fewer patients than might be expected, possibly due to the slower titration rate than in the RCTs. Overall in the real-world studies, the most common AEs were somnolence/sedation (17%-46%) and dizziness (17%-27%), with ataxia, behavioral disturbances, nausea, falls, unsteadiness, cognitive slowing, and depression also being reported; behavioral disturbances included aggression (3%-23%) and irritability (2%-18%). 68, 69 Retention rates ranged from 44%-89%. 69 Perampanel discontinuation due to AEs was 23% in 1 study, with the most common reasons being fatigue, behavioral problems, and coordination problems (dizziness, falls), 70 but 39% in a prospective audit, with the most common reasons being nausea, ataxia, depression, dizziness, somnolence, and irritability/aggression. 71 AEs tended to occur more frequently in patients taking a greater number of concomitant AEDs (≤2 vs >2). 67 Psychiatric AEs (primarily irritability or anxiety) occurred more frequently in patients with than without prior psychiatric comorbidities (depression, anxiety, psychosis, personality disorder, and hyperactivity). 68 schedule. 68 Thus, slow titration (approximately ≤2 mg every 2 weeks), tailored to the individual patient, is recommended, particularly for adolescents and patients with psychiatric comorbidity, family history of psychiatric disorders, learning difficulties, or dementia, and dose reduction may be considered. 69, 72 Some AEs such as somnolence and dizziness can be mitigated by taking perampanel at bedtime. 69 Counseling about the potential for, and close monitoring of, psychiatric AEs (including irritability and aggression) during titration, particularly for patients with a psychiatric history, is important. 68, 73 It is worth noting that the cytochrome P450 (CYP)3A4-inducing AEDs carbamazepine, oxcarbazepine, phenytoin and, to a lesser degree, topiramate may increase perampanel clearance, thereby reducing serum levels. 74 In particular, carbamazepine substantially lowers perampanel serum levels, which may result in reduced efficacy of perampanel, thus higher perampanel doses may be needed for patients taking concomitant carbamazepine, albeit on an individual patient basis. 69 
| Real-world clinical experience

| Elderly patients
Perampanel efficacy was similar for adults and adolescents in the real-world studies, but elderly people with refractory focal seizures experienced greater seizure freedom than younger patients. 68, 69 In a comparison of the efficacy and tolerability of perampanel in 20 elderly patients (mean age 69.8 years) and 65 younger patients (mean age 36.8 years) with refractory focal seizures, 75.0% of elderly patients and 53.8% of younger patients were still taking perampanel after 57 months, and 35.0% of elderly patients attained seizure freedom compared with 13.8% of younger patients (P = .009). 75 In this study, older patients also experienced fewer AEs than younger patients (35.0% and 55.4%, respectively; P = .563). Speech effects and fatigue were the most common AEs in the elderly group, whereas vertigo and psychiatric effects were more common in younger patients. In the Spanish study, age older than 65 years was associated with significantly greater seizure freedom than younger age (P = .026) among patients with focal seizures with or without secondary generalization.
68
A subanalysis to the 3, phase-3 trials of patients with focal seizures with or without secondary generalization compared the 28 patients older than 65 years with 1307 adult patients (age ≥18 to <65 years) from the same studies. 76 for placebo in adult patients. Dizziness, fatigue, and fall occurred more frequently in elderly patients than in the adult subgroup, but the higher risk of falls could be associated with age-related comorbidities. Therefore, slower dose titration, especially toward higher doses, could be beneficial for this group.
| Children and adolescents
Because adolescents are in the process of neurological and behavioral change, it is important to establish the impact of AEDs on cognition and development. 77 A study of the relationship between perampanel exposure and cognitive function found similar pharmacokinetics of perampanel for adolescents (age 12-17 years) as for adults. 77 In adolescents with focal seizures, increasing perampanel exposure had no significant effect on overall cognition, measured by the CDR System Global Cognition Score, Quality of Working Memory, or Speed of Memory.
Power of Attention and Continuity of Attention worsened slightly with increasing perampanel concentration, while Quality of Episodic Memory improved slightly. These inconsistencies between perampanel exposure and cognitive function might be due to other factors and the effect of epilepsy on cognitive function should be considered when weighing risk-benefit profiles. An RCT of adolescents (age 12-17 years) with focal seizures with or without secondary generalization showed a median reduction in seizure frequency from baseline of 58.0% for perampanel and 24.0% for placebo (P = .079), and responder rates of 59.0% and 37.0%, respectively (P = .0144). 79 Behavioral changes, measured by the Child
Behavior Checklist before and after treatment, were minimal and there were no differences between groups for competency (P = .619) or problems (P = .174). Aggression was reported more frequently in the perampanel group than in the placebo group (8.2% vs 2.1%). A European retrospective observational survey provides data for pediatric patients treated with perampanel, although a pediatric investigation plan is now underway. 80 Fifty-eight patients (mean age 10.5 years; range 2-17 years) with various refractory epilepsies were enrolled, including focal seizures, unclassified generalized epilepsy, Lennox-Gastaut syndrome, West syndrome, and Dravet syndrome. After 3 months, the responder rate was 31%, and 9% of patients achieved seizure freedom. Although the numbers of patients in each group were small, analysis by etiology, syndrome, or seizure type found that those with structural-metabolic epilepsy (response 38%) or epilepsy of unknown etiology (29%) had better results than those with genetic epilepsy (18%). Patients with Dravet syndrome (50%), Lennox-Gastaut syndrome (40%), focal epilepsy (33%), or unclassified generalized epilepsy (25%) had better results than those with West syndrome (0%). Among the disabling seizures, patients with epileptic spasms (67%), generalized myoclonic (50%), atypical absence (50%), focal (30%), generalized tonic (25%), and GTC (25%) seizures had better responses than those with myoclonic absence seizures (0%). Children aged 6 years and older tended to have a better response than younger children (36% vs 9%). Five patients (9%) experienced seizure aggravation. The most frequent AEs were reduced vigilance or fatigue and behavioral changes, with children younger than 12 years having a more favorable AE profile.
An Italian observational retrospective study enrolled 62 patients aged 6-18 years (mean age 14.2 years). 81 Most patients (62.9%) had symptomatic focal epilepsy, but some patients had epileptic encephalopathy or generalized seizures. The epilepsy etiologies included congenital malformation, cryptogenic, hypoxic-ischemic, genetic, or idiopathic, and epilepsy syndromes included Lennox-Gastaut, Doose, Dravet, PCDH19-related epilepsy, and tuberous sclerosis complex. After a mean follow-up of 6.6 months, the retention rate was 77.4%. The responder rate was 50.0%, 16.1% of patients achieved ≥75% seizure frequency reduction and 4.8% achieved seizure freedom. Older children (adolescents) had a better response than children younger than 12 years (53.7% vs 25.0%). The overall number of seizures decreased after perampanel initiation (z-score À5.770, P < .001 Wilcoxon test), and patients with hypoxic-ischemic, congenital malformative, or cryptogenic seizures had better outcomes. Seizure aggravation occurred in 9.7% of patients. Due to its novel mechanism of action, perampanel could be considered a rational combination therapy in adolescent patients with focal seizures who have not achieved control with other AEDs. 82 Although the tolerability profile in adolescents was generally favorable in the phase 3 trials, young patients receiving perampanel should be monitored for AEs related to irritability and aggression, particularly during dose titration and at higher doses. There are risks associated with seizures occurring in pregnancy, both to the woman and the fetus, and these must be balanced against the potential for risks to the fetus from pharmacotherapy. 83, 84 As it is not possible to conduct well-controlled studies in pregnant women, a database of pregnancies occurring in women in the perampanel phase 3 RCTs has been compiled. 84 As of April 2015, there have been 25 pregnancies in 22 women, of which 12 resulted in induced abortion, five in spontaneous abortion, five in the birth of a healthy infant, and one in neonatal death; 2 patients were lost to follow-up. Of the five healthy births, the duration of possible exposure for the fetus was 22-107 days.
| Other epilepsies with multiple seizure types
Progressive myoclonus epilepsies are typically associated with generalized motor seizures, usually tonic-clonic, tonic vibratory, myoclonic or clonic, and stimulus-sensitive or action myoclonus. 85 Treatment is challenging, as some AEDs can aggravate myoclonus and myoclonic seizures, including vigabatrin, carbamazepine, phenytoin, and gabapentin. Traditional AEDs for the treatment of progressive myoclonus epilepsies include valproate, clonazepam, and phenobarbital (or primidone), whereas newer drugs include piracetam, levetiracetam, topiramate, zonisamide, and perampanel. Two case reports have suggested efficacy of perampanel for Lafora disease. 86, 87 In the first report, a young woman achieved a sustained and reproducible remission of myoclonus and GTC seizures for 3 months with perampanel 8 mg/d as adjunctive therapy. 87 Although the seizures recurred after reducing the dose to 6 mg, control was achieved for a further 3 months on increasing the dose to 10 mg, and the patient regained the ability to walk with assistance. In the second report, an adolescent girl experienced worsening myoclonic jerks and frequent GTC seizures despite taking multiple AEDs, so her parents stopped all medication. 86 They were reluctant to restart the previous medications, so perampanel monotherapy was initiated and rapidly titrated to10 mg daily. Perampanel resulted in amelioration of myoclonus and GTC seizure frequency, and a marked improvement in activities of daily living. After 1 month, the patient was able to walk unassisted and cognitive function improved. 86 In an open trial of 10 patients with Lafora disease, perampanel (mean dose 6.7 mg) was added to the medication regimen. 88 Overall, the average number of GTC seizures per 28 days was 6.14 at baseline, which decreased to 2.29 and 2.86 at the months 3 and 9, respectively. Four patients had reduction in seizure frequency per 28 days of >74%, 7
had improvement in myoclonus intensity from 7.01 at baseline to 5.67 and 5.18, respectively. Three patients withdrew because of lack of effect or AEs. Perampanel has also been prescribed as add-on therapy for drug-resistant posthypoxic myoclonus (Lance-Adams syndrome). 89 The patient had almost continuous stimulussensitive polytopic myoclonic jerks that required the permanent use of a wheelchair despite therapy with levetiracetam, valproic acid, clonazepam, piracetam, and lacosamide. Addition of perampanel 4 mg almost completely suppressed the myoclonic jerks, so lacosamide and piracetam were discontinued. Withdrawal of perampanel due to somnolence resulted in prominent myoclonus, which subsided after reintroduction of perampanel 4 mg. After 4 weeks of therapy, myoclonus remained suppressed and somnolence had decreased to a tolerable level. When perampanel was given as add-on therapy for 12 patients with Unverricht-Lundborg disease, 10 experienced a clear clinical response of myoclonus, some at a dose as low as 2 mg, and 5 were able to reduce their concomitant medication. 90 Epileptic seizures stopped in all 6 patients who experienced generalized tonic-clonic or myoclonic seizures (100%). The most frequent AEs were weight gain and psychological or behavioral changes, including irritability/aggression, anxiety/depression, and hallucinations. These AEs occurred at higher rates than in the clinical trials and limited its use at higher doses (~6 mg/d); the expected AEs of fatigue, somnolence, and dizziness were not noted.
| Status epilepticus
Several reports suggest that perampanel might be useful in the treatment of SE. A small retrospective study of 9 patients with complicated refractory nonconvulsive SE and simple partial motor SE found that perampanel was the terminating drug in 2-6 of 10 episodes, depending on the criteria used to measure efficacy. 51 Using the preferred criteria (last drug introduced within 72 or 24 hours before cessation of SE, without changes in comedication), perampanel was effective in 3-4 episodes. In a retrospective chart review of 12 patients with refractory SE (nonconvulsive with or without coma), perampanel was given at an initial dose of 4 mg (range 2-12 mg), titrated at 2-4 mg/d to 12 mg (range 4-12 mg). 91 Two patients had clinical and EEG improvement. The relatively low response rate might be due to oral administration of perampanel, the long duration of SE before administration, and the severe underlying brain dysfunction in these patients. Further research on the tolerability and safety of higher doses and earlier administration of perampanel for treatment of refractory SE is warranted.
In a single case of refractory hypoxic myoclonic status, a middle-aged patient had clinical and EEG myoclonic SE during therapeutic hypothermia after acute myocardial infarction, which worsened during rewarming. 92 After several treatments had been tried, including clonazepam, valproate, sedation (midazolam, propofol), and barbiturateinduced coma, perampanel 6 mg, increasing to 8 mg, was given via a nasogastric tube. There was a marked improvement in EEG activity and resolution of myoclonus. The patient experienced progressive clinical improvement with recovery of consciousness. Perampanel has been effective in treating epilepsia partialis continua and seizures due to Rasmussen encephalitis. 93 The patient had a history of temporal lobe resection and perioperative intracerebral hemorrhage, and had been treated with various combination therapies, usually of at least 4 AEDs at any 1 time. At the time of referral, the patient was experiencing focal seizures with myoclonic jerks. Perampanel 6 mg was introduced, and he became seizure free after 3 days. Further study of perampanel for these indications might be useful.
| Other seizures
Brain tumors, particularly gliomas, are associated with seizures, possibly because of interactions between the mechanisms that cause the 2 conditions. 94 Seizures occur in up to 90% of patients with low-grade gliomas and 50%-60% of patients with high-grade gliomas. The site of epileptic activity is usually close to the tumor, at the interface between the tumor and the surrounding tissues, where excessive extracellular glutamate release and glutamate receptor activation promotes glioma growth and neuronal excitability. AEDs are frequently used to control seizures in neurological malignancies. 94, 95 As well as having antiepileptic effects, perampanel may contribute to tumor control by blocking the AMPA receptor, as overexpression of the AMPA receptor aids proliferation and migration of glioma cells. 96 In a small series of 12 patients, perampanel 2-12 mg resulted in a 50% seizure response in 3 (25%) and seizure-freedom in 6 (50%). Perampanel has also been shown to be efficacious against seizures in 1 patient with glioblastoma multiforme. 
T A B L E 2 Licensed indications for AEDs
| Place of perampanel in treatment
There are few direct comparisons of the newer AEDs, and no direct comparisons of perampanel with other AEDs. In time to treatment failure, lamotrigine was significantly better than carbamazepine, gabapentin and topiramate and had a nonsignificant advantage compared with oxcarbazepine. 8 For idiopathic generalized and unclassified epilepsies, valproate was the drug of choice over topiramate and lamotrigine, except for women of childbearing age. 7 Perampanel was not licensed when these studies were conducted, so was not included ( Table 2 shows the licensed indications for the newer AEDs discussed in this review). An indirect comparison of brivaracetam, eslicarbazepine, lacosamide, and perampanel found no differences between the drugs for responder rates and seizure freedom in patients with uncontrolled focal epilepsy. 98 Brivaracetam and lacosamide had a lower risk of TEAEs than high-dose perampanel and eslicarbazepine, but there was no difference between the drugs for TEAEs leading to study/treatment discontinuation. A single-center retrospective chart review compared the first 70 consecutive patients to receive perampanel after its introduction with the first 70 consecutive patients to receive lacosamide when it first became available in 2008. 99 After 6 months of treatment, the 50% responder rates were 48.6% for perampanel and 28.6% for lacosamide, Seizure freedom was achieved by 14.3% of perampanel patients and 4.3% of lacosamide patients.
A meta-analysis of 7823 patients with SGTC seizures in 24 RCTs was done to investigate potential differences in response to AEDs. 100 63 However, the place of perampanel in the treatment hierarchy is hard to determine given the lack of studies directly comparing perampanel with other AEDs and the differences (eg, methods, patient populations, endpoints) in the trials comparing other AEDs with placebo.
63,101 
| CONCLUSION
The studies in preclinical epilepsy models and clinical evidence show that perampanel has antiepileptogenic potential and is well tolerated and effective for treatment of focal seizures with or without secondary generalization, PGTC seizures, and other seizure types. In addition, there is extensive clinical experience with perampanel in real-world patients. It is notable that perampanel has not been shown to aggravate other seizure types such as absence or myoclonic seizures. Because perampanel is a first-in-class AED with a unique mechanism of action and potential for broad-spectrum efficacy, it is a useful adjunctive therapy for patients with refractory focal seizures, with or without secondary generalization, and PGTC seizures, and might be an effective option for rational polytherapy. Ultimately, the choice of AED may be tailored to patient factors, seizure type, and drug characteristics.
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